Cargando…

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

INTRODUCTION: There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rountree, Susan D, Chan, Wenyaw, Pavlik, Valory N, Darby, Eveleen J, Siddiqui, Samina, Doody, Rachelle S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874259/ https://www.ncbi.nlm.nih.gov/pubmed/19845950 http://dx.doi.org/10.1186/alzrt7

Ejemplares similares

Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Correction: Predicting progression of Alzheimer's disease
por: Doody, Rachelle S, et al.
Publicado: (2010)

Factors that influence survival in a probable Alzheimer disease cohort
por: Rountree, Susan D, et al.
Publicado: (2012)

Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment
por: Pavlik, Valory N, et al.
Publicado: (2011)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?
por: Fox, Chris, et al.
Publicado: (2006)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
por: Bent-Ennakhil, Nawal, et al.
Publicado: (2017)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
por: Dou, Kai-Xin, et al.
Publicado: (2018)

Validity, Significance, Strengths, Limitations, and Evidentiary Value of Real-World Clinical Data for Combination Therapy in Alzheimer's Disease: Comparison of Efficacy and Effectiveness Studies
por: Atri, Alireza, et al.
Publicado: (2012)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil and Camicioli
por: Tariot, Pierre N., et al.
Publicado: (2014)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

Cognitively-Related Basic Activities of Daily Living Impairment Greatly Increases the Risk of Death in Alzheimers Disease
por: Liang, Fu-Wen, et al.
Publicado: (2016)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2018)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

Memantine as an Augmentation Therapy for Anxiety Disorders
por: Schwartz, Thomas L., et al.
Publicado: (2012)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
por: Pavlik, Valory N., et al.
Publicado: (2022)

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia
por: Zuin, Marco, et al.
Publicado: (2022)

Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
por: Zhang, Yunpeng, et al.
Publicado: (2019)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment
por: Wang, Xiaochuan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i4r5j29i0frnqls35120c2jlq8